TIDMPAHC 
 
RNS Number : 5006Z 
Phibro Animal Health Corporation 
23 September 2009 
 

For release: IMMEDIATE 
 
 
 
 
PHIBRO ANIMAL HEALTH CORPORATION ANNOUNCES 
SUMMARY ANNUAL RESULTS 
 
 
RIDGEFIELD PARK, New Jersey, 23 September 2009 - Phibro Animal Health 
Corporation ("PAHC" or the "Company") today announced summary annual results for 
its fiscal year ended 30 June 2009.  The information below will be presented at 
a UBS conference on 23 September 2009. The Company expects to release full 
details of its financial results for the year ended 30 June 2009 on or about 28 
September 2009. 
 
 
Sales were $550 million, a $39 million, or 8%, increase over the prior year. The 
recent acquisitions contributed $30 million of the increase. Adjusted ebitda was 
$54 million, a $3 million, or 6%, increase over the prior year. The recent 
acquisitions contributed almost all of the increase. 
 
 
Animal Health & Nutrition sales were $462 million, a $44 million, or 10%, 
increase over the prior year. Adjusted ebitda was $60 million, a $5 million, or 
9% increase over the prior year.  Distribution and Industrial Chemical sales 
totaled $88 million, a $5 million, or 6%, decrease from the prior year and 
adjusted ebitda was $9 million, a $2 million, or 17%, decrease from the prior 
year.  Corporate expenses of $15 million were equal to the prior year. 
 
 
On a pro forma basis, as if the acquisitions had occurred at the beginning of 
the year, sales were $615 million and adjusted ebitda was $61 million. 
 
 
Adjustments to ebitda totaled $6 million and were for acquisition related cost 
of goods sold, impairment of long-lived assets, cost of acquired in-process R&D, 
and severance related to plant consolidations. 
 
 
Cash flow from operating activities was $40 million for the current year, 
including a $21 million source of cash from reduced working capital and payments 
of $29 million for interest and $6 million for income taxes. Capital 
expenditures were $18 million in the current year. 
 
 
Debt at 30 June 2009 consisted of $2 million under the domestic senior credit 
facility, $240 million of senior notes and senior subordinated notes, and $53 
million of other debt, including amounts owed to 3i, Teva and BFI. Cash at 
fiscal year end was $14 million. 
 
 
ABOUT THE COMPANY 
PAHC is a diversified global developer, manufacturer and marketer of a broad 
range of animal health and nutrition products to the poultry, swine, cattle and 
acquaculture markets. PAHC is also a manufacturer and marketer of performance 
products for the ethanol, wood preservation and personal care industries. For 
more information, please visit www.pahc.com. 
 
 
For further information please contact: 
 
 
+------------------------------------------------+--------------------------+ 
| Phibro Animal Health Corporation               | +1 201 329 7300          | 
| Richard Johnson, Chief Financial Officer       |                          | 
| investor.relations@pahc.com                    |                          | 
+------------------------------------------------+--------------------------+ 
+------------------------------------------------+--------------------------+ 
| Panmure Gordon (UK) Limited                    | +44 (0) 207 459 3600     | 
| Andrew Godber                                  |                          | 
| Rakesh Sharma                                  |                          | 
|                                                |                          | 
+------------------------------------------------+--------------------------+ 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 FR CKBKKDBKBFCB
Phibro Animal S (LSE:PAHC)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Phibro Animal S Charts.
Phibro Animal S (LSE:PAHC)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Phibro Animal S Charts.